The relapsed or refractory diffuse large B-cell lymphoma (RRDLBCL) is an aggressive type of non-Hodgkin’s lymphoma (NHL) that usually responds well to first line chemotherapy but often relapses after treatment. The RRDLBCL treatments aim to prolong survival after relapse by improving response and delaying disease progression. The chemotherapy drugs like monoclonal antibodies rituximab,...